SCHEMBL4616751

SCHEMBL4616751

CC(C)c1ccc(S(=O)(=O)c2ccc(F)cc2)cc1S(=O)(=O)NCCc1ccncc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
HTT P42858 5/20 0.52
LMNA P02545 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SFRP1 Q8N474 1/20 0.49
TSHR P16473 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
TAAR1 Q96RJ0 1/20 0.48
USP2 O75604 1/20 0.46
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618000 0.89 ALDH1A1 (0.49) ALDH1A1HTTLMNASMN1; SMN2PKM
SCHEMBL4619248 0.88 TBXAS1 (0.53) ALDH1A1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL4617050 0.86 SFRP1 (0.67) ALDH1A1HTTLMNASMN1; SMN2PKM
SCHEMBL4617754 0.84 CA1 (0.44) ALDH1A1LMNASMN1; SMN2PKMMEN1
SCHEMBL4616468 0.83 HTT (0.60) ALDH1A1HTTLMNASMN1; SMN2PKM
SCHEMBL4619016 0.82 RAB9A (0.49) ALDH1A1HTTSMN1; SMN2PKMSFRP1
SCHEMBL4618309 0.82 SFRP1 (0.72) ALDH1A1HTTLMNAMAPK1MEN1
SCHEMBL4617324 0.82 SFRP1 (0.48) ALDH1A1LMNAMAPK1MEN1KMT2A
SCHEMBL4617326 0.80 SFRP1 (0.40) ALDH1A1SMN1; SMN2PKMMEN1KMT2A
SCHEMBL4637578 0.80 CYP19A1 (0.48) ALDH1A1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 ALDH1A1 1865/4885HTT 4703/4885LMNA 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.